Investigational drug · Phase 3
PORT-77
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP), EPP2.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "PORT-77"
First trial start
2025
Apr 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PORT-77", any sponsor or status.
Conditions studied
As listed on its trial records.
- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)
- EPP2
Approved drugs for the same conditions: Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "PORT-77" as an intervention, largest first.
- A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)Pivotal-lookingRecruiting
Portal Therapeutics, Inc.Industry
NCT07820085 · 225 participants (planned) · Start Sep 2026 · Primary completion Mar 2029
Drug: PORT-77; Placebo · For: Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP); EPP2
Sites: Huntington Beach, California; Cincinnati, Ohio
- Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult ParticipantsPivotal-lookingCompleted
Portal Therapeutics, Inc.Industry
NCT06346509 · 156 participants · Start Apr 8, 2024 · Primary completion Dec 27, 2025
Drug: PORT-77; Placebo · For: Healthy Adult Participants
Sites: Tempe, Arizona
Portal Therapeutics, Inc.Industry
NCT06971900 · 28 participants · Start Apr 4, 2025 · Primary completion Nov 22, 2025
Drug: PORT-77; Placebo · For: Erythropoietic Protoporphyria (EPP)
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Erythropoietic Protoporphyria (EPP)
- DersimelagonMT-7117Phase 32 trials
Tanabe Pharma America, Inc. · EPP, XLP, Erythropoietic Protoporphyria (EPP)
- DISC-1459Bitopertin, RO4917838Phase 32 trials
Disc Medicine, Inc · Erythropoietic Protoporphyria, Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.